PI3K/mTOR inhibitor · small molecule
dactolisib
0 active trials, targeting PI3K/mTOR. Not approved for any biomarker on marked.bio yet.
Also known as BEZ235, NVP-BEZ235.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| PIK3CA activating mutation | 0 | 2 | – |
Trials
0 of 2 trials shown
-
A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors
Patients whose molecular status proved to meet the criteria (PIK3CA mutation/amplification and/or PTEN mutation and/or low/null PTEN expression) during pre-screening.
PIK3CA activating mutationAdvanced Solid Tumor
-
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Eligible patients will have to have tumors carrying molecular alterations of PIK3CA and/or PTEN.
PIK3CA activating mutationBreast Cancer, Advanced Solid Tumors, Cowden Syndrome
No trials match these filters.